These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 29653234

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun 20; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M.
    Ann Allergy Asthma Immunol; 2018 May 20; 120(5):504-511.e4. PubMed ID: 29409951
    [Abstract] [Full Text] [Related]

  • 8. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G.
    Drug Des Devel Ther; 2017 May 20; 11():3137-3144. PubMed ID: 29133975
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan 18; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B, Xue L, Pavord ID.
    Ther Adv Respir Dis; 2015 Aug 18; 9(4):135-45. PubMed ID: 25900924
    [Abstract] [Full Text] [Related]

  • 15. The role of interleukin 5 in asthma.
    Varricchi G, Canonica GW.
    Expert Rev Clin Immunol; 2016 Sep 18; 12(9):903-5. PubMed ID: 27450970
    [No Abstract] [Full Text] [Related]

  • 16. Eosinophils and interleukin-5: the debate continues.
    Kay AB, Menzies-Gow A.
    Am J Respir Crit Care Med; 2003 Jun 15; 167(12):1586-7. PubMed ID: 12796050
    [No Abstract] [Full Text] [Related]

  • 17. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, Yancey SW, Steinfeld J.
    J Allergy Clin Immunol; 2019 Nov 15; 144(5):1336-1342.e7. PubMed ID: 31425781
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
    Numata T, Miyagawa H, Nishioka S, Okuda K, Utsumi H, Hashimoto M, Minagawa S, Ishikawa T, Hara H, Araya J, Kuwano K.
    BMC Pulm Med; 2020 Aug 03; 20(1):207. PubMed ID: 32746787
    [Abstract] [Full Text] [Related]

  • 19. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
    Albers FC, Price RG, Smith SG, Yancey SW.
    J Allergy Clin Immunol; 2017 Nov 03; 140(5):1464-1466.e4. PubMed ID: 28687231
    [No Abstract] [Full Text] [Related]

  • 20. Eosinophils in mucosal immune responses.
    Travers J, Rothenberg ME.
    Mucosal Immunol; 2015 May 03; 8(3):464-75. PubMed ID: 25807184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.